Arcus Biosciences’ August 5 call looks routine, but its biggest pipeline test is approaching
Arcus Biosciences will report Q2 results on August 5 as investors assess casdatifan progress, pipeline execution and its cash runway.
Pharma & Biotech
Pharma & Biotech
Why Vasomune is taking its AV-001 vascular leak strategy into combat casualty medicine
Vasomune Therapeutics will present Pegevongitide at a major military health symposium, positioning vascular leak as a shared target across burns, shock, trauma and acute respiratory distress syndrome.
Pharma & Biotech
Can Cellares automation move Papillon’s PPL-001 closer to a Friedreich’s ataxia trial?
Cellares will automate PPL-001 manufacturing for Friedreich’s ataxia, but IND-enabling work and human evidence remain ahead.
Pharma & Biotech
Evox Therapeutics advances MSH3 Huntington’s disease programme through eXmoor Pharma transfer
eXmoor Pharma and Evox complete an exosome gene-editing transfer, advancing the CMC path for Evox’s Huntington’s disease programme.
Medical Devices & Diagnostics
What Bruker’s DISQVER acquisition means for sepsis and bloodstream infection testing
Bruker acquires DISQVER from Noscendo, adding blood-based clinical metagenomics as it pursues diagnostic registration and wider adoption.
Pharma & Biotech
Evonik and evitria say this CHO kit can cut biologics troubleshooting. Will laboratories make the switch?
Evonik and evitria launch the eviCHO Expression Kit to simplify CHO-K1 protein production, but adoption will depend on reproducible lab performance.
Pharma & Biotech
Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Pharma & Biotech
Can Beam Healthcare and Simvuly turn same-day specialist advice into a practical national care model?
Beam Healthcare and Simvuly take specialist consults nationwide, but workflow, reimbursement and measurable outcomes will decide adoption.
Medical Devices & Diagnostics
LRE Medical calls its IVD framework AI-ready, but the bigger opportunity starts before the algorithm
LRE Medical will showcase a connected IVD framework at ADLM 2026, highlighting cybersecurity, cloud services and future AI integration.
Pharma & Biotech
Pheast Therapeutics strengthens PHST001 case with peer-reviewed anti-CD24 cancer research
Pheast Therapeutics’ PHST001 gains peer-reviewed CD24 data as Phase 1 combination cohorts advance. See what the evidence means.